Dulaglutide Research Peptide — Scientific Overview
Dulaglutide (brand name Trulicity®, developed by Eli Lilly) is a long-acting GLP-1 receptor agonist consisting of two GLP-1 analogs linked to an IgG4 Fc antibody fragment via a short peptide linker. The IgG4 Fc fusion dramatically extends the drug’s half-life (approximately 5 days), enabling once-weekly dosing. Dulaglutide is FDA-approved for Type 2 diabetes management and for cardiovascular risk reduction in patients with T2DM and established cardiovascular disease, based on the REWIND cardiovascular outcomes trial.
Dulaglutide (brand name Trulicity®, developed by Eli Lilly) is a long-acting GLP-1 receptor agonist consisting of two GLP-1 analogs linked to an IgG4 Fc antibody fragment via a short peptide linker. The IgG4 Fc fusion dramatically extends the drug’s half-life (approximately 5 days), enabling once-weekly dosing. Dulaglutide is FDA-approved for Type 2 diabetes management and for cardiovascular risk reduction in patients with T2DM and established cardiovascular disease, based on the REWIND cardiovascular outcomes trial. The REWIND trial (Gerstein et al., NEJM 2019) demonstrated a 12% relative risk reduction in major adverse cardiovascular events (MACE) with dulaglutide versus placebo — the first GLP-1 RA to show CV benefit in patients with lower baseline cardiovascular risk (some without established CVD). Dulaglutide also reduces body weight, blood pressure, and HbA1c. It is used as a well-characterized GLP-1R pharmacological research tool and comparator standard for studying GLP-1R agonism in metabolic, cardiovascular, and renal research models.
Research Background
The REWIND trial (Gerstein et al., NEJM 2019) demonstrated a 12% relative risk reduction in major adverse cardiovascular events (MACE) with dulaglutide versus placebo — the first GLP-1 RA to show CV benefit in patients with lower baseline cardiovascular risk (some without established CVD). Dulaglutide also reduces body weight, blood pressure, and HbA1c. It is used as a well-characterized GLP-1R pharmacological research tool and comparator standard for studying GLP-1R agonism in metabolic, cardiovascular, and renal research models.
Key Research Areas
- GLP-1R Pharmacology Research: GLP-1 receptor agonism, downstream signaling, and β-cell biology
- Cardiovascular Research: MACE reduction, cardiac protection, and GLP-1R cardiac signaling
- Metabolic Research: HbA1c reduction, insulin secretion, and glycemic regulation studies
- Renal Research: Kidney protection, GFR preservation, and renal inflammation studies
- Appetite/Weight Research: GLP-1R-mediated satiety and body weight reduction models
- Comparative Research: Dulaglutide vs. other GLP-1 RAs — potency and duration comparison
Technical Specifications
| Parameter | Value |
|---|---|
| Classification | Long-acting GLP-1 receptor agonist (GLP-1-IgG4 Fc fusion protein) |
| Brand Name | Trulicity® (Eli Lilly) |
| Purity | ≥98% (HPLC-verified) |
| Form | Lyophilized powder, sealed under argon |
| Storage | −20°C (long-term) |
| Documentation | Batch-specific COA (HPLC + Mass Spec) |
Storage & Handling (Research Laboratories)
Lyophilized Dulaglutide should be stored at −20°C for long-term preservation, protected from light and moisture. For short-term active research use, 4°C storage is acceptable for up to approximately 4 weeks. Minimize repeated freeze-thaw cycles. Follow standard laboratory peptide reconstitution and handling protocols for all experimental use.
